Table 2.
Country | No. | Date of RV Introduction | RV Type | 2013/2014 Coverage Estimates, %a | Age Eligible | Age Ineligible | ||||
---|---|---|---|---|---|---|---|---|---|---|
No. (%) | Age (mo), Mean ± SD |
Rotavirus EIA Positive, No. % | No. (%) | Age (mo), Mean ± SD |
Rotavirus EIA Positive, No. (%) | |||||
Burkina Faso | 694 | November 2013 | RotaTeq | 9/91 | 155 (22.3) | 6 ± 2.6 | 27 (17.4) | 539 (77.7) | 11.6 ± 4.3 | 292 (54.2) |
Ghana | 547 | April 2012 | Rotarix | 87/98 | 468 (85.6) | 10.4 ± 4.9 | 152 (32.5) | 79 (14.4) | 17.5 ± 3.6 | 28 (35.4) |
The Gambia | 186 | August 2013 | RotaTeq | 90/92 | 40 (21.5) | 7.5 ± 3.1 | 3 (7.5) | 146 (78.5) | 13.4 ± 5.3 | 41 (28.1) |
Rwanda | 1337 | June 2012 | RotaTeq | >99/98 | 1098 (82.1) | 11 ± 4.3 | 211 (19.2) | 239 (17.9) | 16.2 ± 3.9 | 77 (32.2) |
South Africa | 1086 | August 2009 | Rotarix | 89/94 | 1086 (100) | 9.6 ± 5.2 | 314 (28.9) | 0 (0.0) | NA | NA |
Senegal | 157 | November 2014 | Rotarix | NA/NA | 0 (0.0) | NA | NA | 157 (100.0) | 9.7 ± 5.4 | 66 (42.0) |
Sierra Leone | 307 | April 2014 | Rotarix | NA/70 | 1 (0.3) | 3.0 ± 0.0 | 0 (0.0) | 306 (99.7) | 9.4 ± 4.4 | 142 (46.4) |
Togo | 342 | July 2014 | Rotarix | NA/35 | 0 (0.0) | NA | NA | 342 (100.0) | 10.1 ± 4.6 | 203 (59.4) |
Zambia | 1816 | December 2013 | Rotarix | NA/73 | 374 (20.6) | 6.1 ± 2.4 | 115 (30.7) | 1442 (79.4) | 10.8 ± 5.1 | 565 (39.2) |
Zimbabwe | 1712 | May 2014 | Rotarix | NA/82 | 80 (4.7) | 5.2 ± 1.6 | 19 (23.8) | 1632 (95.3) | 11.1 ± 4.9 | 835 (51.2) |
Overall | 8184 | 3302 (40.3) | 9.5 ± 4.8 | 841 (25.5) | 4882 (59.7) | 11.3 ± 5.1 | 2249 (46.1) |
Abbreviations: EIA, enzyme immunoassay; NA, not applicable; RV, rotavirus vaccine; SD, standard deviation.
aVaccine coverage estimates for a complete course (from the World Health Organization vaccine-preventable disease monitoring system, 2016 global summary; available at: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tscoveragerotac.html).